| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1086/323198 |
| P953 | full work available at URL | http://academic.oup.com/cid/article-pdf/33/11/1901/1221900/33-11-1901.pdf |
| https://academic.oup.com/cid/article-pdf/33/11/1901/1221900/33-11-1901.pdf | ||
| P698 | PubMed publication ID | 11692302 |
| P5875 | ResearchGate publication ID | 11662480 |
| P50 | author | John Ioannidis | Q6251482 |
| P2093 | author name string | J. P. Ioannidis | |
| T. A. Trikalinos | |||
| P2860 | cites work | Prognosis in HIV-1 infection predicted by the quantity of virus in plasma | Q29619980 |
| Pneumonia in HIV-infected patients: a case-control survey of factors involved in risk and prevention | Q33747781 | ||
| Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy | Q33894426 | ||
| Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection | Q34740804 | ||
| Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection | Q38959227 | ||
| HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy | Q39512181 | ||
| Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions | Q39513658 | ||
| Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group | Q39588620 | ||
| Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons | Q39598890 | ||
| Prophylaxis for opportunistic infections in an era of effective antiretroviral therapy. | Q40747905 | ||
| Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. | Q43608936 | ||
| Haemophilus influenzae pneumonia in human immunodeficiency virus-infected patients. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas | Q45743747 | ||
| Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: the HIV outpatient study (HOPS). | Q49075636 | ||
| Recovery of the immune system with antiretroviral therapy: the end of opportunism? | Q52038588 | ||
| Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor | Q52919874 | ||
| Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study | Q56537120 | ||
| Discontinuation of Primary Prophylaxis againstPneumocystis cariniiPneumonia in HIV-1–Infected Adults Treated with Combination Antiretroviral Therapy | Q56539850 | ||
| Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy | Q57388808 | ||
| Discontinuation of Secondary Prophylaxis againstPneumocystis cariniiPneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy | Q57877986 | ||
| Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? | Q57878097 | ||
| A Randomized Trial of the Discontinuation of Primary and Secondary Prophylaxis againstPneumocystis cariniiPneumonia after Highly Active Antiretroviral Therapy in Patients with HIV Infection | Q58204825 | ||
| Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe | Q58291953 | ||
| Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators | Q73394842 | ||
| A new preadmission staging system for predicting inpatient mortality from HIV-associated Pneumocystis carinii pneumonia in the early highly active antiretroviral therapy (HAART) era | Q73675000 | ||
| Bacterial pneumonia in hospitalized patients with HIV infection: the Pulmonary Complications, ICU Support, and Prognostic Factors of Hospitalized Patients with HIV (PIP) Study | Q73681520 | ||
| Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection | Q74025554 | ||
| Analysis of life-long strategies to prevent Pneumocystis carinii pneumonia in patients with variable HIV progression rates | Q77107333 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Pneumocystis carinii | Q2099992 |
| decision analysis | Q5249226 | ||
| P304 | page(s) | 1901-1909 | |
| P577 | publication date | 2001-10-22 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis | |
| Discontinuation ofPneumocystis cariniiProphylaxis in Patients Infected with Human Immunodeficiency Virus: A Meta‐Analysis and Decision Analysis | |||
| P478 | volume | 33 |
| Q50800026 | A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapy |
| Q38596372 | Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis |
| Q26829541 | Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/µL and virologic suppression: a systematic review |
| Q38868223 | HIV-Infected Ugandan Adults Taking Antiretroviral Therapy With CD4 Counts >200 Cells/ L Who Discontinue Cotrimoxazole Prophylaxis Have Increased Risk of Malaria and Diarrhea |
| Q93501240 | HIV: prevention of opportunistic infections |
| Q33850498 | HIV: primary and secondary prophylaxis for opportunistic infections |
| Q77856220 | Management of Opportunistic Infection Prophylaxis in the Highly Active Antiretroviral Therapy Era |
| Q33584240 | Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy |
| Q81205244 | [Markov models in clinical medicine] |
Search more.